India’s pharmaceutical sector is bracing for a game-changing patent expiry this Friday that could make weight-loss drugs far more accessible, not just at home but globally.
Semaglutide, the powerhouse ingredient in Novo Nordisk’s Danish hits Wegovy and Ozempic, enters the generic arena in India on 20 March, paving the way for fierce local competition.
Firms like Cipla, Sun Pharma, Dr Reddy’s, Biocon, Natco, Zydus and Mankind Pharma plan to roll out around 50 branded versions within months, slashing monthly prices from 8,800-16,000 rupees to 3,000-5,000 rupees, according to Pharmarack Vice-President Sheetal Sapale.
This follows familiar patterns in India’s $60 billion industry, projected to double by 2030 and already dominating 20% of world generics exports to over 200 countries. Jefferies calls it a “magic-pill moment,” eyeing $1 billion domestic sales amid soaring demand.
Globally, IQVIA predicts GLP-1 drugs will hit $100 billion by 2030 as obesity afflicts 1 billion adults. These appetite-suppressing injections, mimicking gut hormones for 15-20% weight loss, were diabetes treatments that exploded into slimming stardom.
With 77 million diabetes cases and 135 million overweight Indians, cheaper options arrive timely. Mumbai bariatric surgeon Muffazal Lakdawala welcomes the shift from scarce, pricey injectables. “It is great that these will become cheaper so that more of the diabetic and obese Indian population can access them,” he says, though he stresses tight quality controls. “The quality of the drugs being made here must be very tightly regulated.”
Doctors like Mumbai diabetologist Rahul Baxi caution on risks such as nausea, muscle loss and rebound weight gain. “People come asking to lose 10kg in three months,” Baxi notes, advocating gradual dosing with lifestyle changes. “Gradual weight loss, slow dose escalation, and a focus on protein intake, exercise and strength training are key to healthier outcomes.”
Exports could boom too, says Pharmaceuticals Export Promotion Council chairman Namit Joshi. “The export potential of Indian generic weight-loss drugs is humongous. The U.S. market alone could scale to $10bn within a few years.”
Regulators recently banned direct ads, curbing misuse fears. Baxi is already advising patience, “I am actually writing on prescriptions to many patients: Come to me after 20 March when the prices come down.” If quality holds, India could repeat its HIV generics triumph, democratising obesity care worldwide.